Stress urinary incontinence and overactive bladder syndrome: current options and new targets for management.
In the United States, office visits for women seeking treatment for urinary incontinence more than doubled between 1994 and 2000, from 1845 per 100 000 women. This review article addresses treatment options for 2 common types of incontinence in women: stress urinary incontinence (SUI) and detrusor overactivity (DO), commonly referred to as urge urinary incontinence (UUI). In the past, those with SUI typically faced limited treatment options, such as Kegel exercises, pessaries, or major surgery (Burch or Marshall-Marchetti-Krantz operations). However, treatment options for women also included anticholinergic medications, behavioral therapy, and implantable neuromodulation. In recent years, more options have become available. For women with SUI, a variety of minimally invasive synthetic midurethral sling approaches (eg, retropubic, transobturator, and single incision) and office-based procedures (eg, periurethral injection of bulking agents and radiofrequency collagen denaturation [Renessa®; Novasys Medical]) are now offered. More outpatient options will hopefully be available soon, including an inflatable, free-floating balloon to act as a shock absorber, and injection of muscle-derived stem cells into the periurethral tissue. Women with UUI now have targeted options, such as posterior tibial nerve stimulation (PTNS) and intravesical injections of onabotulinumtoxinA (Botox®; Allergan, Inc.), in addition to nonoral systemic medications.
Women's Health Institute of Illinois, Ltd., Oak Lawn, IL 60453, USA. delser@whii.org
Denise M
DM
Elser
D000083:Acetanilides / Q000627:therapeutic use; D001521:Behavior Therapy; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D017115:Catheter Ablation; D002404:Catheterization; D004599:Electric Stimulation Therapy; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D033581:Stem Cell Transplantation; D053825:Suburethral Slings; D013844:Thiazoles / Q000627:therapeutic use; D053201:Urinary Bladder, Overactive / Q000628:therapy*; D014550:Urinary Incontinence, Stress / Q000628:therapy*; D013520:Urologic Surgical Procedures
D000083:Acetanilides; D009465:Neuromuscular Agents; D013844:Thiazoles; D019274:Botulinum Toxins, Type A; C520025:mirabegron